Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT newswireMT newswire2026/09/02 14:59
10:59 AM EDT, 09/02/2026 (MT Newswires) -- Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly $13 billion valuation, upside looks limited ahead of the data, RBC Capital Markets said in a note Wednesday. Kymera's phase IIb KT-621 data in atopic dermatitis are expected by year-end 2026. A placebo-adjusted EASI percentage change from baseline of about 35% and an EASI-75 rate of 35% to 40% would be enough to support the view of KT-621 as an "oral Dupixent," the analysts said. The analysts added that while they think the drug is more likely than not to succeed, Kymera's roughly $13 billion fully diluted market cap already reflects significant expectations. Given the $11 billion value set in AbbVie's acquisition of Apogee Therapeutics following positive phase II atopic-dermatitis data, RBC said Kymera's risk-reward setup appears balanced. The analysts said they would seek a better entry point or further progress before recommending investors add to positions. RBC has a Sector Perform rating and a $112 price target on Kymera Therapeutics. Price: 118.65, Change: -0.40, Percent Change: -0.34
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Bank of America survey: Long semiconductors remains the world's most crowded trade, but the level of crowding has nearly halved from the July peak

A Bank of America survey shows that 39% of fund managers consider going long on semiconductors to be the most crowded trade. Although it remains the top position, this figure has dropped significantly from the July peak of 82%, indicating that positions are starting to loosen.

智通财经•2026/11/18 08:11

Energy shock not widespread? UK inflation hits one-year high but falls short of central bank expectations, traders scale back rate hike bets

Driven by a sharp increase in energy bills and vehicle fuel prices, inflation in the UK has accelerated, reaching its highest level in a year.

智通财经•2026/11/18 08:11
Energy shock not widespread? UK inflation hits one-year high but falls short of central bank expectations, traders scale back rate hike bets